Olga Morozova
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Olga Morozova has a total of 126 co-authors. Here are the top co-authors by number of shared publications:
- Forrest W. Crawford
Department of Biostatistics, Yale School of Public Health, New Haven, USA
9 shared publications - Kostyantyn Dumchev
Ukrainian Institute on Public Health Policy, Kyiv, Ukraine
9 shared publications - Frederick L. Altice
Yale University
8 shared publications - Sergii Dvoriak
Ukrainian Institute on Public Health Policy, Kyiv, Ukraine
5 shared publications Kostyantyn Dumchev
Ukrainian Institute on Public Health Policy, Kyiv, Ukraine
4 shared publications- Sean A. P. Clouston
Stony Brook University
4 shared publications
Latest Publications
- Open Access
- 23 March 2026
- Published by Wiley in Influenza and Other Respiratory Viruses
- Vol. 20 (3) , e70253
Immune Priming and the Risk of COVID‐19, Influenza, and Other Acute Respiratory Infections: Insights From an N3C Cohort
Background: The emergence of SARS‐CoV‐2 and introduction of COVID‐19 vaccines into immunologically naïve populations may alter the dynamics of other acute viral respiratory infections (viral ARIs) and vice versa. Competing forces, including viral interference, cross‐reactive immunity, shared susceptibility, and immune dysregulation, may affect the risk. The potential net impact of various immune‐priming events and their timing on the risk of viral ARIs is largely unknown. Methods: Using data from the National Clinical Cohort Collaborative (N3C) COVID‐19 Enclave, this retrospective population‐based cohort study investigated the relationship between immune‐priming events (COVID‐19 and influenza vaccinations, and SARS‐CoV‐2, influenza, other, and unspecified viral ARIs) between January 2018 and September 2021 and the risk of viral ARIs during October 2021–April 2022. The sample included N = 608,725 individuals from seven data partners with well‐ascertained COVID‐19 and influenza vaccination data. Results: Early COVID‐19 vaccination (December 2020–March 2021) and SARS‐CoV‐2 infection during the overlapping period (October 2020–March 2021) were associated with a lower risk of all outcomes, including non‐SARS‐CoV‐2 infections. Off‐season influenza vaccination (January–June 2021) was associated with a lower risk of SARS‐CoV‐2 and any viral ARI. Other priming events showed mixed associations, with a lack of evidence of stronger protection from more recent immune‐priming events. Conclusions: This exploratory analysis suggests potential crossprotection between viral ARIs that may inform vaccination strategies. While ascertainment and healthcare‐seeking biases in electronic health records may inflate positive associations between infection outcomes and immune priming, negative (i.e., protective) associations are of potential public health significance and warrant further investigation.
- 23 March 2026
- Published by Wiley in Influenza and Other Respiratory Viruses
- Vol. 20 (3) , e70253
Open AccessImmune Priming and the Risk of COVID‐19, Influenza, and Other Acute Respiratory Infections: Insights From an N3C Cohort
Background: The emergence of SARS‐CoV‐2 and introduction of COVID‐19 vaccines into immunologically naïve populations may alter the dynamics of other acute viral respiratory infections (viral ARIs) and vice versa. Competing forces, including viral interference, cross‐reactive immunity, shared susceptibility, and immune dysregulation, may affect the risk. The potential net impact of various immune‐priming events and their timing on the risk of viral ARIs is largely unknown. Methods: Using data from the National Clinical Cohort Collaborative (N3C) COVID‐19 Enclave, this retrospective population‐based cohort study investigated the relationship between immune‐priming events (COVID‐19 and influenza vaccinations, and SARS‐CoV‐2, influenza, other, and unspecified viral ARIs) between January 2018 and September 2021 and the risk of viral ARIs during October 2021–April 2022. The sample included N = 608,725 individuals from seven data partners with well‐ascertained COVID‐19 and influenza vaccination data. Results: Early COVID‐19 vaccination (December 2020–March 2021) and SARS‐CoV‐2 infection during the overlapping period (October 2020–March 2021) were associated with a lower risk of all outcomes, including non‐SARS‐CoV‐2 infections. Off‐season influenza vaccination (January–June 2021) was associated with a lower risk of SARS‐CoV‐2 and any viral ARI. Other priming events showed mixed associations, with a lack of evidence of stronger protection from more recent immune‐priming events. Conclusions: This exploratory analysis suggests potential crossprotection between viral ARIs that may inform vaccination strategies. While ascertainment and healthcare‐seeking biases in electronic health records may inflate positive associations between infection outcomes and immune priming, negative (i.e., protective) associations are of potential public health significance and warrant further investigation.
- 1 February 2026
- Published by American College of Physicians in Annals of Internal Medicine
- Vol. 179 (2) , 177-186
Integrating Methadone Services Into Primary Care in Ukraine: Two-Year Outcomes From a Randomized Trial
Opioid use disorder (OUD) drives high morbidity and mortality, but access to opioid agonist therapy (OAT) is limited in low- and middle-income countries. Integrating OAT into primary care may expand access and improve comorbidity management, although provider discomfort remains a barrier. To compare health care use among persons with OUD receiving methadone in specialty clinics versus primary care centers in Ukraine (January 2018 to December 2023). Two-group randomized controlled trial with 2:1 allocation to intervention and control. (ClinicalTrials.gov: NCT04927091). Thirteen cities in Ukraine: Cherkasy, Dnipro, Kramatorsk, Kropyvnytskyi, Kryvyi Rih, Kyiv, Lviv, Mariupol, Mykolaiv, Odesa, Rivne, Sloviansk, and Zhytomyr. A total of 1459 adults with OUD (950 intervention, 509 control) initiating or receiving methadone. Methadone delivered in primary care aided with telementoring, an Extension for Community Healthcare Outcomes-like model that is adapted to the Ukraine context, versus standard specialty clinic care. Primary outcome: difference in composite quality health indicator (QHI) scores between groups at 24 months, representing access to 17 guideline-concordant services (9 primary care and 8 specialty care) received, assessed through surveys and ranging from 0 to 100. Secondary outcomes: domain-specific QHI scores and methadone treatment indicators. Participants in primary care settings achieved higher composite QHI scores than those in specialty clinics, with a mean difference of 9.1 percentage points (95% CI, 6.9 to 11.2 percentage points) at 24 months. Results were similar for primary care QHI (12.3 percentage points [CI, 9.0 to 15.6 percentage points]) and specialty care QHI (5.2 percentage points [CI, 0.2 to 10.3 percentage points]). Methadone retention among new patients at 24 months was 67.2% in primary care versus 64.7% in specialty clinics. Quality health indicators reflect health care use rather than health outcomes. Quality health indicators were equally weighted despite differing clinical significance. Integrating methadone treatment into primary care settings improves adherence to guideline-concordant health care without compromising methadone retention and treatment quality. National Institute on Drug Abuse.
- 1 February 2026
- Published by American College of Physicians in Annals of Internal Medicine
- Vol. 179 (2) , 177-186
Integrating Methadone Services Into Primary Care in Ukraine: Two-Year Outcomes From a Randomized Trial
Opioid use disorder (OUD) drives high morbidity and mortality, but access to opioid agonist therapy (OAT) is limited in low- and middle-income countries. Integrating OAT into primary care may expand access and improve comorbidity management, although provider discomfort remains a barrier. To compare health care use among persons with OUD receiving methadone in specialty clinics versus primary care centers in Ukraine (January 2018 to December 2023). Two-group randomized controlled trial with 2:1 allocation to intervention and control. (ClinicalTrials.gov: NCT04927091). Thirteen cities in Ukraine: Cherkasy, Dnipro, Kramatorsk, Kropyvnytskyi, Kryvyi Rih, Kyiv, Lviv, Mariupol, Mykolaiv, Odesa, Rivne, Sloviansk, and Zhytomyr. A total of 1459 adults with OUD (950 intervention, 509 control) initiating or receiving methadone. Methadone delivered in primary care aided with telementoring, an Extension for Community Healthcare Outcomes-like model that is adapted to the Ukraine context, versus standard specialty clinic care. Primary outcome: difference in composite quality health indicator (QHI) scores between groups at 24 months, representing access to 17 guideline-concordant services (9 primary care and 8 specialty care) received, assessed through surveys and ranging from 0 to 100. Secondary outcomes: domain-specific QHI scores and methadone treatment indicators. Participants in primary care settings achieved higher composite QHI scores than those in specialty clinics, with a mean difference of 9.1 percentage points (95% CI, 6.9 to 11.2 percentage points) at 24 months. Results were similar for primary care QHI (12.3 percentage points [CI, 9.0 to 15.6 percentage points]) and specialty care QHI (5.2 percentage points [CI, 0.2 to 10.3 percentage points]). Methadone retention among new patients at 24 months was 67.2% in primary care versus 64.7% in specialty clinics. Quality health indicators reflect health care use rather than health outcomes. Quality health indicators were equally weighted despite differing clinical significance. Integrating methadone treatment into primary care settings improves adherence to guideline-concordant health care without compromising methadone retention and treatment quality. National Institute on Drug Abuse.
- Open Access
- 2 January 2026
- Published by Elsevier in International Journal of Drug Policy
- Vol. 148, 105107
Initiation, retention, and discontinuation of extended-release buprenorphine (BUP-XR) for opioid dependence: A single-arm multi-site trial in Ukraine
- 2 January 2026
- Published by Elsevier in International Journal of Drug Policy
- Vol. 148, 105107
Open AccessInitiation, retention, and discontinuation of extended-release buprenorphine (BUP-XR) for opioid dependence: A single-arm multi-site trial in Ukraine
- Open Access
- 1 August 2025
- Published by Wolters Kluwer Health in JAIDS Journal of Acquired Immune Deficiency Syndromes
- Vol. 99 (4) , 395-404
HIV Viral Rebound on Dolutegravir, Lopinavir, and Efavirenz: National Program Data Analysis From Ukraine
Background: Dolutegravir (DTG), an integrase strand transfer inhibitor, is recommended as the preferred first-line HIV medication globally because of higher efficacy, better tolerability, and higher genetic barrier to resistance compared with other antiretroviral therapy (ART) drug classes. However, little is known about the comparative effectiveness of DTG in sustaining durable viral suppression (VS) in real-world settings. Methods: We analyzed data from electronic health records of a retrospective cohort of ART-naïve (N = 3793) and ART-experienced (N = 14,367) people receiving HIV treatment in Ukraine between October 2017 and September 2018, comparing incidence of viral rebound (viral load ≥ 200 HIV RNA copies/mL) after the first documented VS among participants on DTG-, ritonavir-boosted lopinavir–, and efavirenz-based regimens. Participants were followed until June 2019. Interval censoring survival analysis with cluster-robust standard errors was used to estimate the effects of ART regimen on viral rebound adjusting for demographic and clinical characteristics. Results: N = 714 (3.9%) participants experienced viral rebound during follow-up. In the ART-naïve cohort, the incidence of rebound was 6.9 events [95% confidence interval (CI): 5.9 to 8.0] per 100 person-years. Ritonavir-boosted lopinavir-based regimens were associated with higher hazard of rebound compared with DTG-based regimens: adjusted hazard ratio = 1.8 (95% CI: 1.3 to 2.4). Efavirenz-based regimens had similar incidence of rebound compared with DTG: adjusted hazard ratio = 1.1 (95% CI: 0.9 to 1.3). Conclusions: Favorable performance of DTG compared with other first-line ART options in sustaining VS supports continued roll-out of DTG-based regimens. High overall incidence of viral rebound, including on DTG-based regimens, calls for targeted evidence-based adherence support interventions and improved viral load and drug resistance monitoring, especially among high-risk populations.
- 1 August 2025
- Published by Wolters Kluwer Health in JAIDS Journal of Acquired Immune Deficiency Syndromes
- Vol. 99 (4) , 395-404
Open AccessHIV Viral Rebound on Dolutegravir, Lopinavir, and Efavirenz: National Program Data Analysis From Ukraine
Background: Dolutegravir (DTG), an integrase strand transfer inhibitor, is recommended as the preferred first-line HIV medication globally because of higher efficacy, better tolerability, and higher genetic barrier to resistance compared with other antiretroviral therapy (ART) drug classes. However, little is known about the comparative effectiveness of DTG in sustaining durable viral suppression (VS) in real-world settings. Methods: We analyzed data from electronic health records of a retrospective cohort of ART-naïve (N = 3793) and ART-experienced (N = 14,367) people receiving HIV treatment in Ukraine between October 2017 and September 2018, comparing incidence of viral rebound (viral load ≥ 200 HIV RNA copies/mL) after the first documented VS among participants on DTG-, ritonavir-boosted lopinavir–, and efavirenz-based regimens. Participants were followed until June 2019. Interval censoring survival analysis with cluster-robust standard errors was used to estimate the effects of ART regimen on viral rebound adjusting for demographic and clinical characteristics. Results: N = 714 (3.9%) participants experienced viral rebound during follow-up. In the ART-naïve cohort, the incidence of rebound was 6.9 events [95% confidence interval (CI): 5.9 to 8.0] per 100 person-years. Ritonavir-boosted lopinavir-based regimens were associated with higher hazard of rebound compared with DTG-based regimens: adjusted hazard ratio = 1.8 (95% CI: 1.3 to 2.4). Efavirenz-based regimens had similar incidence of rebound compared with DTG: adjusted hazard ratio = 1.1 (95% CI: 0.9 to 1.3). Conclusions: Favorable performance of DTG compared with other first-line ART options in sustaining VS supports continued roll-out of DTG-based regimens. High overall incidence of viral rebound, including on DTG-based regimens, calls for targeted evidence-based adherence support interventions and improved viral load and drug resistance monitoring, especially among high-risk populations.
- Open Access
- 8 January 2025
- Published by Elsevier in The Lancet Regional Health - Americas
- Vol. 42, 100984
SARS-COV-2 re-infection and incidence of post-acute sequelae of COVID-19 (PASC) among essential workers in New York: a retrospective cohort study
- 8 January 2025
- Published by Elsevier in The Lancet Regional Health - Americas
- Vol. 42, 100984
Open AccessSARS-COV-2 re-infection and incidence of post-acute sequelae of COVID-19 (PASC) among essential workers in New York: a retrospective cohort study
- Open Access
- 19 July 2024
- Published by Wiley in Journal of the International AIDS Society
- Vol. 27 (S3) , e26319
Patterns of daily oral HIV PrEP adherence among people who inject drugs in Ukraine: an analysis of biomarkers
Introduction: Daily oral HIV pre‐exposure prophylaxis (PrEP) with tenofovir/emtricitabine (TDF/FTC) is recommended for people who inject drugs (PWID) but coverage is low. The real‐life effectiveness of PrEP among PWID is unknown as previous studies were conducted in controlled settings and mainly relied on self‐report. Analysis of PrEP metabolites—tenofovir diphosphate (TFVdp) and emtricitabine triphosphate (FTCtp)—offers an objective measure of adherence.Methods: To analyse longitudinal patterns of PrEP adherence among PWID in Ukraine, we used data from a community‐based implementation trial conducted in Kyiv between July 2020 and March 2021 to test the efficacy of SMS reminders to improve adherence. Among 199 enrolled participants, 156 (78.4%) were retained through 6 months. Based on TFVdp/FTCtp levels assessed at 3 and 6 months, we identified groups with various adherence patterns (adherent at ≥2 doses/week, improved, worsened, non‐adherent). Correlates of adherence were analysed using multinomial logistic regression.Results: Most participants (53.8%, n = 84/156) had no detectable metabolites at both assessments; 7.1% (n = 11/156) were consistently taking ≥2 doses/week; 1.3% (n = 2/156) were consistently taking ≥4 doses/week; 13.5% (n = 21/156) exhibited improved and 21.8% (n = 34/156) had worsened adherence at 6 compared to 3 months. “White coat compliance” (increased dosing prior to assessment) was common. Consistent adherence was associated with SMS reminders, younger age, employment, lower income, longer injection drug use duration, recent high‐risk injecting (receptive syringe sharing, using pre‐filled syringe, back‐ or front‐loading, container sharing), absence of overdose in the past 6 months, perceived HIV risk through sexual intercourse and higher PrEP self‐efficacy. Alcohol consumption was associated with inconsistent PrEP use. Groups with improved and worsened adherence did not differ.Conclusions: Daily oral PrEP may not achieve the desired effectiveness among PWID as a standalone intervention, calling for testing of alternative PrEP formulations and innovative integrated risk reduction strategies, especially in the context of HIV epidemics associated with injection drug use in eastern Europe and central Asia and the public health crisis in Ukraine caused by the war with Russia. SMS reminders may be effective among PWID who prioritize PrEP. Our findings offer practical guidance in identifying PWID who are likely to benefit from PrEP and those who need additional support.
- 19 July 2024
- Published by Wiley in Journal of the International AIDS Society
- Vol. 27 (S3) , e26319
Open AccessPatterns of daily oral HIV PrEP adherence among people who inject drugs in Ukraine: an analysis of biomarkers
Introduction: Daily oral HIV pre‐exposure prophylaxis (PrEP) with tenofovir/emtricitabine (TDF/FTC) is recommended for people who inject drugs (PWID) but coverage is low. The real‐life effectiveness of PrEP among PWID is unknown as previous studies were conducted in controlled settings and mainly relied on self‐report. Analysis of PrEP metabolites—tenofovir diphosphate (TFVdp) and emtricitabine triphosphate (FTCtp)—offers an objective measure of adherence.Methods: To analyse longitudinal patterns of PrEP adherence among PWID in Ukraine, we used data from a community‐based implementation trial conducted in Kyiv between July 2020 and March 2021 to test the efficacy of SMS reminders to improve adherence. Among 199 enrolled participants, 156 (78.4%) were retained through 6 months. Based on TFVdp/FTCtp levels assessed at 3 and 6 months, we identified groups with various adherence patterns (adherent at ≥2 doses/week, improved, worsened, non‐adherent). Correlates of adherence were analysed using multinomial logistic regression.Results: Most participants (53.8%, n = 84/156) had no detectable metabolites at both assessments; 7.1% (n = 11/156) were consistently taking ≥2 doses/week; 1.3% (n = 2/156) were consistently taking ≥4 doses/week; 13.5% (n = 21/156) exhibited improved and 21.8% (n = 34/156) had worsened adherence at 6 compared to 3 months. “White coat compliance” (increased dosing prior to assessment) was common. Consistent adherence was associated with SMS reminders, younger age, employment, lower income, longer injection drug use duration, recent high‐risk injecting (receptive syringe sharing, using pre‐filled syringe, back‐ or front‐loading, container sharing), absence of overdose in the past 6 months, perceived HIV risk through sexual intercourse and higher PrEP self‐efficacy. Alcohol consumption was associated with inconsistent PrEP use. Groups with improved and worsened adherence did not differ.Conclusions: Daily oral PrEP may not achieve the desired effectiveness among PWID as a standalone intervention, calling for testing of alternative PrEP formulations and innovative integrated risk reduction strategies, especially in the context of HIV epidemics associated with injection drug use in eastern Europe and central Asia and the public health crisis in Ukraine caused by the war with Russia. SMS reminders may be effective among PWID who prioritize PrEP. Our findings offer practical guidance in identifying PWID who are likely to benefit from PrEP and those who need additional support.
- Open Access
- 19 July 2024
- Published by Wiley in Journal of the International AIDS Society
- Vol. 27 (S3) , e26307
“Will you need this health at all? Will you be alive?”: using the bioecological model of mass trauma to understand HIV care experiences during the war in Ukraine
Introduction: Russia's invasion of Ukraine in February 2022 has severely impacted the healthcare system, including the provision of HIV care. The ongoing war is a human‐caused mass trauma, a severe ecological and psychosocial disruption that greatly exceeds the coping capacity of the community. The bioecological model of mass trauma builds on Bronfenbrenner's concept of interaction between nested systems to argue that social context determines the impact of life events on the individual and how an individual responds. This paper uses the bioecological model of mass trauma to explore the impact of Russia's aggression against Ukraine and the ongoing war on HIV‐positive people who use drugs in Ukraine, a particularly vulnerable population that may be negatively affected by disruptions to social networks, healthcare infrastructure and economic conditions caused by mass trauma.Methods: Data were collected between September and November 2022. A convenience sample of 18 HIV‐positive people who use drugs were recruited from community organizations that work with people living with HIV, drug treatment programmes, and HIV clinics through direct recruitment and participant referral. A total of nine men and nine women were recruited; the age ranged from 33 to 62 years old (mean = 46.44). Participants completed a single interview that explored how the war had affected their daily lives and access to HIV care and other medical services; their relationships with healthcare providers and social workers; and medication access, supply and adherence. Data were analysed using the Framework Method for thematic analysis.Results: The war had a profound impact on the social, emotional and financial support networks of participants. Changes in social networks, coupled with limited job opportunities and rising prices, intensified financial difficulties for participants. Relocating to different regions of Ukraine, staying at somebody else's home, and losing connections with social workers impacted medication adherence and created lengthy treatment gaps. Participants also experienced a decreased supply of antiretroviral therapy, concerns about accessing medication for opioid use disorder, and overwhelming fears associated with the war, which overshadowed their HIV‐related health concerns and negatively impacted medication adherence.Conclusions: Our analysis reveals the complex impact of war on social networks and healthcare access. Maintaining support networks and competent healthcare providers will be essential amid the ongoing war.
- 19 July 2024
- Published by Wiley in Journal of the International AIDS Society
- Vol. 27 (S3) , e26307
Open Access“Will you need this health at all? Will you be alive?”: using the bioecological model of mass trauma to understand HIV care experiences during the war in Ukraine
Introduction: Russia's invasion of Ukraine in February 2022 has severely impacted the healthcare system, including the provision of HIV care. The ongoing war is a human‐caused mass trauma, a severe ecological and psychosocial disruption that greatly exceeds the coping capacity of the community. The bioecological model of mass trauma builds on Bronfenbrenner's concept of interaction between nested systems to argue that social context determines the impact of life events on the individual and how an individual responds. This paper uses the bioecological model of mass trauma to explore the impact of Russia's aggression against Ukraine and the ongoing war on HIV‐positive people who use drugs in Ukraine, a particularly vulnerable population that may be negatively affected by disruptions to social networks, healthcare infrastructure and economic conditions caused by mass trauma.Methods: Data were collected between September and November 2022. A convenience sample of 18 HIV‐positive people who use drugs were recruited from community organizations that work with people living with HIV, drug treatment programmes, and HIV clinics through direct recruitment and participant referral. A total of nine men and nine women were recruited; the age ranged from 33 to 62 years old (mean = 46.44). Participants completed a single interview that explored how the war had affected their daily lives and access to HIV care and other medical services; their relationships with healthcare providers and social workers; and medication access, supply and adherence. Data were analysed using the Framework Method for thematic analysis.Results: The war had a profound impact on the social, emotional and financial support networks of participants. Changes in social networks, coupled with limited job opportunities and rising prices, intensified financial difficulties for participants. Relocating to different regions of Ukraine, staying at somebody else's home, and losing connections with social workers impacted medication adherence and created lengthy treatment gaps. Participants also experienced a decreased supply of antiretroviral therapy, concerns about accessing medication for opioid use disorder, and overwhelming fears associated with the war, which overshadowed their HIV‐related health concerns and negatively impacted medication adherence.Conclusions: Our analysis reveals the complex impact of war on social networks and healthcare access. Maintaining support networks and competent healthcare providers will be essential amid the ongoing war.
- 27 June 2024
- Published by Springer Nature in International Journal of Mental Health and Addiction
- Vol. 23 (6) , 4310-4327
Prevalence and Correlates of Depression and Bipolar Disorder Among Patients Maintained on Methadone and Buprenorphine in Ukraine
Psychiatric and substance use disorders frequently coexist and require co-management, yet little is known about the prevalence of psychiatric disorders among patients maintained on medications for opioid use disorder (MOUD) in Ukraine. We analyzed baseline data from a cluster-randomized trial of an integrated model of depression diagnosis and treatment among MOUD patients in Ukraine to determine prevalence and correlates of depression and bipolar disorder in this population. From a randomly selected sample of 1345 patients on MOUD at 12 sites in Ukraine, screening for moderate/severe depression (PHQ-9) and bipolar disorder (MDQ) yielded high prevalence of 50% (95% CI 42–58%) and 12% (95% CI 8–16%), respectively. Correlates of depression included recent drug injection, worse physical health, shorter duration on MOUD, higher methadone dosages, and stigma levels, being unmarried and having low trust in physicians. Bipolar disorder was correlated with alcohol use disorder and prior incarceration. The high burden of mental health disorders among patients prescribed MOUD in Ukraine calls for the urgent implementation of models to address co-occurring disorders, including those using integrated care strategies.
- 27 June 2024
- Published by Springer Nature in International Journal of Mental Health and Addiction
- Vol. 23 (6) , 4310-4327
Prevalence and Correlates of Depression and Bipolar Disorder Among Patients Maintained on Methadone and Buprenorphine in Ukraine
Psychiatric and substance use disorders frequently coexist and require co-management, yet little is known about the prevalence of psychiatric disorders among patients maintained on medications for opioid use disorder (MOUD) in Ukraine. We analyzed baseline data from a cluster-randomized trial of an integrated model of depression diagnosis and treatment among MOUD patients in Ukraine to determine prevalence and correlates of depression and bipolar disorder in this population. From a randomly selected sample of 1345 patients on MOUD at 12 sites in Ukraine, screening for moderate/severe depression (PHQ-9) and bipolar disorder (MDQ) yielded high prevalence of 50% (95% CI 42–58%) and 12% (95% CI 8–16%), respectively. Correlates of depression included recent drug injection, worse physical health, shorter duration on MOUD, higher methadone dosages, and stigma levels, being unmarried and having low trust in physicians. Bipolar disorder was correlated with alcohol use disorder and prior incarceration. The high burden of mental health disorders among patients prescribed MOUD in Ukraine calls for the urgent implementation of models to address co-occurring disorders, including those using integrated care strategies.
- Open Access
- 26 June 2024
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 19 (6) , e0305072
Modes of HIV transmission among young women and their sexual partners in Ukraine
Background: Ukraine has the second-largest HIV epidemic in Europe, with most new cases officially attributed to heterosexual transmission. Indirect evidence suggested substantial HIV transmission from people who inject drugs (PWID) to their sexual partners. This study examined the extent of heterosexual HIV transmission between PWID and non-drug-using adolescent girls and young women (AGYW). Methods: A cross-sectional survey recruited AGYW diagnosed with heterosexually-acquired HIV between 2016 and 2019 in nine regions of Ukraine. AGYW were asked to identify and refer their sexual partners (‘Partners’), who subsequently underwent HIV testing, and, if positive, HCV testing. Both AGYW and Partners completed an interview assessing HIV risk behaviors prior to AGYW’s HIV diagnosis. Results: In August-December 2020, we enrolled 321 AGYW and 64 Partners. Among the Partners, 42% either self-reported IDU or were HCV-positive, indicating an IDU-related mode of HIV transmission. PWID Partners were more likely to report sexually transmitted infections (STI) and had lower educational levels. Of the 62 women who recruited at least one Partner, 40% had a PWID Partner. Within this subgroup, there was a higher prevalence of STIs (52% vs. 24%) and intimate partner violence (36% vs. 3%). Condom use was less common (52% vs. 38% reporting never use), and frequent alcohol or substance use before sex was higher (48% vs 30%) among AGYW with PWID Partner, although this difference did not reach statistical significance. Notably, 52% of women were aware of their Partners’ IDU. Conclusion: At least 40% of heterosexual transmission among AGYW in Ukraine can be linked to PWID partners. Intensified, targeted HIV prevention efforts are essential for key and bridge populations (PWID and their sexual partners), addressing the biological and structural determinants of transmission between key and bridge populations, such as IDU- and HIV status disclosure, STIs, IPV, and stigma.
- 26 June 2024
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 19 (6) , e0305072
Open AccessModes of HIV transmission among young women and their sexual partners in Ukraine
Background: Ukraine has the second-largest HIV epidemic in Europe, with most new cases officially attributed to heterosexual transmission. Indirect evidence suggested substantial HIV transmission from people who inject drugs (PWID) to their sexual partners. This study examined the extent of heterosexual HIV transmission between PWID and non-drug-using adolescent girls and young women (AGYW). Methods: A cross-sectional survey recruited AGYW diagnosed with heterosexually-acquired HIV between 2016 and 2019 in nine regions of Ukraine. AGYW were asked to identify and refer their sexual partners (‘Partners’), who subsequently underwent HIV testing, and, if positive, HCV testing. Both AGYW and Partners completed an interview assessing HIV risk behaviors prior to AGYW’s HIV diagnosis. Results: In August-December 2020, we enrolled 321 AGYW and 64 Partners. Among the Partners, 42% either self-reported IDU or were HCV-positive, indicating an IDU-related mode of HIV transmission. PWID Partners were more likely to report sexually transmitted infections (STI) and had lower educational levels. Of the 62 women who recruited at least one Partner, 40% had a PWID Partner. Within this subgroup, there was a higher prevalence of STIs (52% vs. 24%) and intimate partner violence (36% vs. 3%). Condom use was less common (52% vs. 38% reporting never use), and frequent alcohol or substance use before sex was higher (48% vs 30%) among AGYW with PWID Partner, although this difference did not reach statistical significance. Notably, 52% of women were aware of their Partners’ IDU. Conclusion: At least 40% of heterosexual transmission among AGYW in Ukraine can be linked to PWID partners. Intensified, targeted HIV prevention efforts are essential for key and bridge populations (PWID and their sexual partners), addressing the biological and structural determinants of transmission between key and bridge populations, such as IDU- and HIV status disclosure, STIs, IPV, and stigma.